Proton Magnetic Resonance Spectroscopy in Multiple Sclerosis

Neuroimaging Clinics of North America

Volumn 19, Issue 1, 2009, Pages 45-58

  Sajja, Balasrinivasa R ^a   Wolinsky, Jerry S ^b   Narayana, Ponnada A ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Brain metabolites; Multiple sclerosis; Proton magnetic resonance spectroscopy

Indexed keywords

N ACETYLASPARTIC ACID;

BRAIN LEVEL; CELL LOSS; CLINICAL PRACTICE; COMPREHENSION; COMPUTER; COMPUTER PROGRAM; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SIGNAL NOISE RATIO; STANDARDIZATION; THERAPY EFFECT;

BRAIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS;

EID: 57049160388     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2008.08.002     Document Type: Review

References (118)

1. Rovaris M., Comi G., and Filippi M. The role of non-conventional MR techniques to study multiple sclerosis patients. J Neurol Sci 186 Suppl 1 (2001) S3-S9
2. Narayana P.A., Doyle T.J., Lai D., et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 43 1 (1998) 56-71
3. Narayana P.A. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 15 4 Suppl (2005) 46S-57S
4. Wolinsky J.S., and Narayana P.A. Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. Curr Opin Neurol 15 3 (2002) 247-251
5. Gonzalez-Toledo E., Kelley R.E., and Minagar A. Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis. Neurol Res 28 3 (2006) 280-283
6. Lin A., Ross B.D., Harris K., et al. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2 2 (2005) 197-214
7. Bitsch A., Bruhn H., Vougioukas V., et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 20 9 (1999) 1619-1627
8. Hurd R., Sailasuta N., Srinivasan R., et al. Measurement of brain glutamate using TE-averaged PRESS at 3 T. Magn Reson Med 51 3 (2004) 435-440
9. Srinivasan R., Sailasuta N., Hurd R., et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128 Pt 5 (2005) 1016-1025
10. Frahm J., and Hanefeld F. Localized proton magnetic resonance spectroscopy of brain disorders in childhood. In: Bachelard H.S. (Ed). Advances in neurochemistry vol. 18 (1997), Plenum, New York 329-402
11. Brand A., Richter-Landsberg C., and Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15 3-5 (1993) 289-298
12. De Stefano N., and Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging 17 Suppl 1 (2007) 31S-35S
13. De Stefano N., Filippi M., Miller D., et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 69 20 (2007) 1942-1952
14. Gonen O., Viswanathan A.K., Catalaa I., et al. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 40 5 (1998) 684-689
15. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508 (1987) 333-348
16. Frahm J., Merboldt K.-D., and Hanicke W. Localized proton spectroscopy using stimulated echoes. J Magn Reson 72 3 (1987) 502-508
17. Posse S., DeCarli C., and Le Bihan D. Three-dimensional echo-planar MR spectroscopic imaging at short echo times in the human brain. Radiology 192 3 (1994) 733-738
18. Sharma R., Narayana P.A., and Wolinsky J.S. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler 7 4 (2001) 221-226
19. Maudsley A.A., Matson G.B., Hugg J.W., et al. Reduced phase encoding in spectroscopic imaging. Magn Reson Med 31 6 (1994) 645-651
20. Posse S., Tedeschi G., Risinger R., et al. High speed 1H spectroscopic imaging in human brain by echo planar spatial-spectral encoding. Magn Reson Med 33 1 (1995) 34-40
21. Mathiesen H.K., Tscherning T., Sorensen P.S., et al. Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. Magn Reson Med 53 4 (2005) 750-759
22. Pruessmann K.P., Weiger M., Scheidegger M.B., et al. SENSE: sensitivity encoding for fast MRI. Magn Reson Med 42 5 (1999) 952-962
23. Griswold M.A., Jakob P.M., Heidemann R.M., et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med 47 6 (2002) 1202-1210
24. Lin F.H., Tsai S.Y., Otazo R., et al. Sensitivity-encoded (SENSE) proton echo-planar spectroscopic imaging (PEPSI) in the human brain. Magn Reson Med 57 2 (2007) 249-257
25. Tsai S.Y., Otazo R., Posse S., et al. Accelerated proton echo planar spectroscopic imaging (PEPSI) using GRAPPA with a 32-channel phased-array coil. Magn Reson Med 59 5 (2008) 989-998
26. Otazo R., Tsai S.Y., Lin F.H., et al. Accelerated short-TE 3D proton echo-planar spectroscopic imaging using 2D-SENSE with a 32-channel array coil. Magn Reson Med 58 6 (2007) 1107-1116
27. Mader I., Seeger U., Weissert R., et al. Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. Brain 124 Pt 5 (2001) 953-961
28. Gonen O., and Grossman R.I. The accuracy of whole brain N-acetylaspartate quantification. Magn Reson Imaging 18 10 (2000) 1255-1258
29. Benedetti B., Rigotti D.J., Liu S., et al. Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol 28 1 (2007) 72-75
30. Rigotti D.J., Inglese M., and Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 28 10 (2007) 1843-1849
31. Jansen J.F., Backes W.H., Nicolay K., et al. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 240 2 (2006) 318-332
32. Li B.S., Wang H., and Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging 21 8 (2003) 923-928
33. Narayana P.A., Wolinsky J.S., Rao S.B., et al. Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis. Mult Scler 10 Suppl 1 (2004) S73-S78
34. Keevil S.F., Barbiroli B., Brooks J.C., et al. Absolute metabolite quantification by in vivo NMR spectroscopy: II. a multicentre trial of protocols for in vivo localised proton studies of human brain. Magn Reson Imaging 16 9 (1998) 1093-1106
35. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30 6 (1993) 672-679
36. Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14 4 (2001) 260-264
37. Doyle T.J., Pathak R., Wolinsky J.S., et al. Automated proton spectroscopic image processing. J Magn Reson B 106 1 (1995) 58-63
38. Maudsley A.A., Wu Z., Meyerhoff D.J., et al. Automated processing for proton spectroscopic imaging using water reference deconvolution. Magn Reson Med 31 6 (1994) 589-595
39. Mierisova S., and Ala-Korpela M. MR spectroscopy quantitation: a review of frequency domain methods. NMR Biomed 14 4 (2001) 247-259
40. Kaartinen J., Mierisova S., Oja J.M., et al. Automated quantification of human brain metabolites by artificial neural network analysis from in vivo single-voxel 1H NMR spectra. J Magn Reson 134 1 (1998) 176-179
41. Hiltunen Y., Kaartinen J., Pulkkinen J., et al. Quantification of human brain metabolites from in vivo 1H NMR magnitude spectra using automated artificial neural network analysis. J Magn Reson 154 1 (2002) 1-5
42. Marshall I., Higinbotham J., Bruce S., et al. Use of Voigt lineshape for quantification of in vivo 1H spectra. Magn Reson Med 37 5 (1997) 651-657
43. Bhat H., Sajja B.R., and Narayana P.A. Fast quantification of proton magnetic resonance spectroscopic imaging with artificial neural networks. J Magn Reson 183 1 (2006) 110-122
44. Naressi A., Couturier C., Devos J.M., et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 12 2-3 (2001) 141-152
45. Maudsley A.A., Darkazanli A., Alger J.R., et al. Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging. NMR Biomed 19 4 (2006) 492-503
46. Adams H.P., Wagner S., Sobel D.F., et al. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Eur Neurol 42 1 (1999) 52-63
47. Davie C.A., Barker G.J., Thompson A.J., et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatr 63 6 (1997) 736-742
48. He J., Inglese M., Li B.S., et al. Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience. Radiology 234 1 (2005) 211-217
49. Arnold D.L., De Stefano N., Narayanan S., et al. Proton MR spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 10 4 (2000) 789-798 ix-x
50. Wolinsky J.S., Narayana P.A., and Fenstermacher M.J. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 40 11 (1990) 1764-1769
51. Larsson H.B., Christiansen P., Jensen M., et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med 22 1 (1991) 23-31
52. Davie C.A., Hawkins C.P., Barker G.J., et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117 Pt 1 (1994) 49-58
53. Trapp B.D., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 5 (1998) 278-285
54. Reddy H., Narayanan S., Matthews P.M., et al. Relating axonal injury to functional recovery in MS. Neurology 54 1 (2000) 236-239
55. De Stefano N., Matthews P.M., and Arnold D.L. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 34 5 (1995) 721-727
56. Mader I., Roser W., Kappos L., et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 21 7 (2000) 1220-1227
57. Arnold D.L., Matthews P.M., Francis G.S., et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31 3 (1992) 235-241
58. De Stefano N., Matthews P.M., Antel J.P., et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 38 6 (1995) 901-909
59. Filippi M., and Agosta F. Magnetization transfer MRI in multiple sclerosis. J Neuroimaging 17 Suppl 1 (2007) 22S-26S
60. Rovaris M., and Filippi M. Diffusion tensor MRI in multiple sclerosis. J Neuroimaging 17 Suppl 1 (2007) 27S-30S
61. Fu L., Matthews P.M., De Stefano N., et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121 Pt 1 (1998) 103-113
62. Husted C.A., Goodin D.S., Hugg J.W., et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 36 2 (1994) 157-165
63. Narayanan S., Fu L., Pioro E., et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 41 3 (1997) 385-391
64. Sarchielli P., Presciutti O., Pelliccioli G.P., et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 122 Pt 3 (1999) 513-521
65. Bjartmar C., Kinkel R.P., Kidd G., et al. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57 7 (2001) 1248-1252
66. Tartaglia M.C., Narayanan S., De Stefano N., et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol 249 10 (2002) 1382-1390
67. Filippi M., Rocca M.A., Martino G., et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 43 6 (1998) 809-814
68. Chard D.T., Griffin C.M., McLean M.A., et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125 Pt 10 (2002) 2342-2352
69. Tiberio M., Chard D.T., Altmann D.R., et al. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol 253 2 (2006) 224-230
70. Leary S.M., Davie C.A., Parker G.J., et al. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 246 11 (1999) 1023-1026
71. Inglese M., Li B.S., Rusinek H., et al. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 50 1 (2003) 190-195
72. Suhy J., Rooney W.D., Goodkin D.E., et al. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 6 3 (2000) 148-155
73. Tourbah A., Stievenart J.L., Abanou A., et al. Normal-appearing white matter in optic neuritis and multiple sclerosis: a comparative proton spectroscopy study. Neuroradiology 41 10 (1999) 738-743
74. Fernando K.T., McLean M.A., Chard D.T., et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 127 Pt 6 (2004) 1361-1369
75. Wattjes M.P., Harzheim M., Lutterbey G.G., et al. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28 8 (2007) 1517-1522
76. Wattjes M.P., Harzheim M., Lutterbey G.G., et al. High field MR imaging and 1H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol 255 1 (2008) 56-63
77. Minagar A. Gray matter involvement in multiple sclerosis: a new window into pathogenesis. J Neuroimaging 13 4 (2003) 291-292
78. Stadelmann C., Albert M., Wegner C., et al. Cortical pathology in multiple sclerosis. Curr Opin Neurol 21 3 (2008) 229-234
79. Bedell B.J., and Narayana P.A. Implementation and evaluation of a new pulse sequence for rapid acquisition of double inversion recovery images for simultaneous suppression of white matter and CSF. J Magn Reson Imaging 8 3 (1998) 544-547
80. Geurts J.J., Pouwels P.J., Uitdehaag B.M., et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 236 1 (2005) 254-260
81. Geurts J.J., Bo L., Pouwels P.J., et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 26 3 (2005) 572-577
82. Nelson F., Poonawalla A.H., Hou P., et al. Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 28 9 (2007) 1645-1649
83. Dehmeshki J., Chard D.T., Leary S.M., et al. The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol 250 1 (2003) 67-74
84. Rovaris M., Bozzali M., Iannucci G., et al. Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. Arch Neurol 59 9 (2002) 1406-1412
85. Poonawalla A.H., Hasan K.M., Gupta R.K., et al. Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis: initial findings. Radiology 246 3 (2008) 880-886
86. Kapeller P., McLean M.A., Griffin C.M., et al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 248 2 (2001) 131-138
87. Sijens P.E., Mostert J.P., Oudkerk M., et al. (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol 16 2 (2006) 489-495
88. Van Au Duong M., Audoin B., Le Fur Y., et al. Relationships between gray matter metabolic abnormalities and white matter inflammation in patients at the very early stage of MS: a MRSI study. J Neurol 254 7 (2007) 914-923
89. Geurts J.J., Reuling I.E., Vrenken H., et al. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 55 3 (2006) 478-483
90. Adalsteinsson E., Langer-Gould A., Homer R.J., et al. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 24 10 (2003) 1941-1945
91. Sarchielli P., Presciutti O., Tarducci R., et al. Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis. J Neurol 249 7 (2002) 902-910
92. Cifelli A., Arridge M., Jezzard P., et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 52 5 (2002) 650-653
93. Bakshi R., Benedict R.H., Bermel R.A., et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 59 1 (2002) 62-68
94. Wylezinska M., Cifelli A., Jezzard P., et al. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 60 12 (2003) 1949-1954
95. Birnbaum G., Leist T.P., and Lublin F.D. Commentary I: pathophysiologic construct for neuronal degeneration/regeneration in multiple sclerosis. Neurology 68 Suppl 3 (2007) S2-S4
96. Gonen O., Catalaa I., Babb J.S., et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 54 1 (2000) 15-19
97. Rovaris M., Gallo A., Falini A., et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 62 6 (2005) 898-902
98. Ge Y., Gonen O., Inglese M., et al. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 62 4 (2004) 624-627
99. Filippi M., Bozzali M., Rovaris M., et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126 Pt 2 (2003) 433-437
100. Tartaglino L.M., Friedman D.P., Flanders A.E., et al. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 195 3 (1995) 725-732
101. Bastianello S., Paolillo A., Giugni E., et al. MRI of spinal cord in MS. J Neurovirol 6 Suppl 2 (2000) S130-S133
102. Ganter P., Prince C., and Esiri M.M. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 25 6 (1999) 459-467
103. DeLuca G.C., Ebers G.C., and Esiri M.M. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 127 Pt 5 (2004) 1009-1018
104. Blamire A.M., Cader S., Lee M., et al. Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopy. Magn Reson Med 58 5 (2007) 880-885
105. Marliani A.F., Clementi V., Albini-Riccioli L., et al. Quantitative proton magnetic resonance spectroscopy of the human cervical spinal cord at 3 Tesla. Magn Reson Med 57 1 (2007) 160-163
106. Kendi A.T., Tan F.U., Kendi M., et al. MR spectroscopy of cervical spinal cord in patients with multiple sclerosis. Neuroradiology 46 9 (2004) 764-769
107. Ciccarelli O., Wheeler-Kingshott C.A., McLean M.A., et al. Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 130 Pt 8 (2007) 2220-2231
108. Arnold D.L. Evidence for neuroprotection and remyelination using imaging techniques. Neurology 68 22 Suppl 3 (2007) S83-S90 [discussion: S86-91]
109. Khan O., Shen Y., Caon C., et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11 6 (2005) 646-651
110. Comi G., Filippi M., and Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian glatiramer acetate study group. Ann Neurol 49 3 (2001) 290-297
111. Paty D.W., and Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI study group and the IFNB multiple sclerosis study group. Neurology 43 4 (1993) 662-667
112. Narayanan S., Caramanos Z., and Arnold D. The effect of glatiramer acetate treatment on axonal integrity in multiple sclerosis. [abstract]. Mult Scler 10 Suppl 2 (2004) S256 Abstract P633
113. 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term H-MRS monitoring in multiple sclerosis. J Neuroimaging 18 3 (2008) 314-319
114. Sajja B.R., Narayana P.A., Wolinsky J.S., et al. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler 14 1 (2008) 73-80
115. Wolinsky J.S., Narayana P.A., O'Connor P., et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61 1 (2007) 14-24
116. Schubert F., Seifert F., Elster C., et al. Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. MAGMA 14 3 (2002) 213-222
117. Sarchielli P., Presciutti O., Tarducci R., et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatr 64 2 (1998) 204-212
118. Narayanan S., De Stefano N., Francis G.S., et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248 11 (2001) 979-986